A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

3 NET are rare but increasingly diagnosed tumors that originate from neuroendocrine cells of the ... trial—regardless of primary tumor site and grade. This FDA approval marks a meaningful ...

Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin ...

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or placebo was 13.8 months vs 3.3 months ... regardless of primary tumor site and grade.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...